Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Professor Gregory Yh Lip

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail

Direct comparison of dabigatran, apixaban, rivaroxaban and edoxaban for effectiveness and safety among patients with non-valvular atrial fibrillation

Doctor E. Choi (Seoul, KR)

Presentation thumbnail

Efficacy and safety of dronedarone by duration of atrial fibrillation history: a post-hoc analysis of the ATHENA trial

Professor M. Blomstrom-Lundqvist (Orebro, SE)

Abstract Slides

Presentation thumbnail

Clinical characteristics and 1-year outcomes in atrial fibrillation patients with or without history of intracranial haemorrhage treated with edoxaban: snapshot analysis of the Global ETNA-AF program

Professor P. Kirchhof (Hamburg, DE)

Presentation thumbnail

Dual antithrombotic therapy is similarly effective to triple therapy in preventing thrombotic events in patients with atrial fibrillation and acute coronary syndrome

Professor Z. Motovska (Prague, CZ)

Abstract Slides

Presentation thumbnail

Use of direct oral anticoagulants in patients with atrial fibrillation having a history of intracranial hemorrhage

Doctor T. Chao (Taipei, TW)

Access the full session

Session thumbnail

Poster Session 5 - Atrial fibrillation and oral anticoagulation 5

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

Congress Presentation

Interactive discussion and Q&A

Congress Session

Oral anticoagulation in subclinical atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources